ACCOUNTS - Final Accounts preparation

Registered number: 14140139

CellResearch Consumer Health Limited

Financial statements

Information for filing with the registrar

For the year ended 31 December 2024

CellResearch Consumer Health Limited

Registered number: 14140139

Balance sheet

As at 31 December 2024

		2024		2023
Note		£		£


Current assets
Debtors: amounts falling due within one year	4	10,106		1,776
Cash at bank and in hand	5	95,203		21,854
		105,309		23,630
Creditors: amounts falling due within one year	6	(106,172)		(24,242)
Net current liabilities			(863)		(612)
Total assets less current liabilities			(863)		(612)

Net liabilities			(863)		(612)

Capital and reserves
Called up share capital	100	100
Profit and loss account	(963)	(712)
	(863)	(612)

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

................................................

Gavin Tan Boon Keat

Director

Date: 3 October 2025

The notes on pages 2 to 5 form part of these financial statements.

Page 1

CellResearch Consumer Health Limited

Notes to the financial statements

For the year ended 31 December 2024

1.	General information

The Company is incorporated and domiciled in England. The Company’s registered office is at Springfield House, Springfield Road, Horsham, West Sussex, RH12 2RG, United Kingdom. The company's registered number is 14140139.
The principal activities of the company are those of the wholesale of cosmetics.
The figures in the financial statements are presented in sterling and have been rounded to the nearest £1.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2

Going concern

The directors have assessed the balance sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the company has adequate resources and reliant on the parent company and group to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

2.3

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 2

CellResearch Consumer Health Limited

Notes to the financial statements

For the year ended 31 December 2024

2.Accounting policies (continued)

2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

∙the company has transferred the significant risks and rewards of ownership to the buyer;

∙the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;

∙the amount of revenue can be measured reliably;

∙it is probable that the company will receive the consideration due under the transaction; and

∙the costs incurred or to be incurred in respect of the transaction can be measured reliably.

2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.8

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of
financial assets and liabilities like trade and other debtors and creditors, loans from banks and other
third parties, loans to related parties and investments in ordinary shares.

Employees

The average monthly number of employees, including directors, during the year was 3 (2023 - 3).

Page 3

CellResearch Consumer Health Limited

Notes to the financial statements

For the year ended 31 December 2024

Debtors

					2024	2023
					£	£


Trade debtors	522	-
Amounts owed by group undertakings	9,205	1,776
Other debtors	379	-
	10,106	1,776

5.	Cash and cash equivalents
		2024	2023
		£	£

	Cash at bank and in hand	95,203	21,854

6.	Creditors: Amounts falling due within one year
		2024	2023
		£	£

Trade creditors	476	-
Amounts owed to group undertakings	104,296	23,822
Other taxation and social security	-	180
Accruals and deferred income	1,400	240
	106,172	24,242

7.	Share capital
		2024	2023
		£	£

Allotted, called up and fully paid

100 (2023 - 100) Ordinary shares shares of £1 each	100	100

Page 4

CellResearch Consumer Health Limited

Notes to the financial statements

For the year ended 31 December 2024

8.	Related party transactions
	The company has taken advantage of the exemption in section 33.1A of FRS102 from disclosing transactions and balances with related parties that are wholly owned by the CellResearch Corporation Pte. Limited.

9.	Controlling party

The company’s immediate holding company is CellResearch Consumer Health Pte. Limited, a company incorporated and domiciled in Singapore. The company's ultimate holding company is CellResearch Corporation Pte. Limited.
The address and principal place of business of the immediate and ultimate holding companies is located at 137 Market Street, #08-02 Grace Global Raffles, Singapore 058953.
Consolidated accounts are submitted by the parent company and can be found using the company name and address above.

10.	Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 3 October 2025 by J A Peach FCA (Senior statutory auditor) on behalf of Kreston Reeves LLP.

Page 5